PROPANC BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
PROPANC BIOPHARMA, INC. (PPCB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 0 shares for the 9-month period ending 2025-03-31, per its 10-Q filed 2025-05-15.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2025-05-15
- PROPANC BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-03-31 was 0.00 shares.
- PROPANC BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-03-31 was 0.00 shares.
- PROPANC BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2019-03-31 was 0.00 shares.
- PROPANC BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2018-12-31 was 0.00 shares.
- PROPANC BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2016 was 143.00M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2025-03-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-15 | 0.00 shares 10-Q · filed 2025-05-15 | ||
| 2024-12-31 | 0.00 shares 10-Q · filed 2025-02-14 | |||
| 2024-03-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-15 | 0.00 shares 10-Q · filed 2025-05-15 | ||
| 2023-12-31 | 0.00 shares 10-Q · filed 2025-02-14 | |||
| 2019-03-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-15 | 0.00 shares derived: sum of 2 quarters · filed 2019-05-15 | 572.00K shares 10-Q · filed 2019-05-15 | |
| 2018-12-31 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-14 | 572.00K shares 10-Q · filed 2019-02-14 | ||
| 2018-09-30 | 572.00K shares 10-Q · filed 2018-11-13 | |||
| 2016-06-30 | 143.00M shares 10-K · filed 2016-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |